Skip to main content
main-content
Top

23-08-2019 | Axial spondyloarthritis | News

guidelinesWatch

US guidelines for the treatment of axSpA published

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: The ACR, Spondylitis Association of America, and Spondyloarthritis Research and Treatment Network have issued updated recommendations for the treatment of ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (axSpA).

This update of the 2015 guidelines “was primarily motivated by the availability of new treatment options, notably secukinumab, ixekizumab, tofacitinib, and TNFi [tumor necrosis factor inhibitors] biosimilars, for patients with axial SpA,” say the authors.

Michael Ward (National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA) recommend that based on current evidence, nonsteroidal anti-inflammatory drugs and TNF inhibitors “remain the primary classes of medications for the treatment of AS and nonradiographic axial SpA,” while the interleukin-17A inhibitors secukinumab and ixekizumab and the Janus kinase inhibitor tofacitinib are recommended in certain situations.

“Application of these recommendations must be individualized, and requires careful assessment, sound clinical judgment of each patient’s circumstances, and consideration of a patient’s preferences,” say Ward et al.

The guidelines are published simultaneously in Arthritis Care & Research and Arthritis & Rheumatology.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

Arthritis Care Res 2019; doi:10.1002/acr.24025
Arthritis Rheumatol 2019; doi:10.1002/art.41042

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

EULAR 2022 Congress coverage

Access the latest news and expert insight from the EULAR 2022 Congress.